iTeos Therapeutics, Inc.
ITOS
$10.13
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | 177.89% | -47.37% | -59.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | 177.89% | -47.37% | -59.30% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -100.00% | -- | 177.89% | -47.37% | -59.30% |
| SG&A Expenses | -10.14% | -7.41% | -2.56% | 1.09% | 6.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.97% | 9.22% | 19.85% | 14.28% | 16.88% |
| Operating Income | -44.90% | 11.45% | -6.35% | -58.87% | -119.21% |
| Income Before Tax | -85.45% | 9.82% | -10.37% | -93.08% | -284.39% |
| Income Tax Expenses | 118.63% | 180.01% | 289.51% | 156.31% | 223.81% |
| Earnings from Continuing Operations | -87.18% | 3.32% | -19.33% | -96.71% | -280.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.18% | 3.32% | -19.33% | -96.71% | -280.67% |
| EBIT | -44.90% | 11.45% | -6.35% | -58.87% | -119.21% |
| EBITDA | -45.08% | 11.68% | -6.15% | -59.17% | -120.56% |
| EPS Basic | -55.69% | 19.47% | -5.10% | -83.13% | -278.99% |
| Normalized Basic EPS | -40.78% | 24.97% | 2.61% | -79.75% | -283.40% |
| EPS Diluted | -55.60% | 19.54% | -5.07% | -80.11% | -265.14% |
| Normalized Diluted EPS | -40.78% | 24.97% | 2.61% | -76.20% | -268.71% |
| Average Basic Shares Outstanding | 17.68% | 18.21% | 13.14% | 8.12% | 3.13% |
| Average Diluted Shares Outstanding | 17.68% | 18.21% | 13.14% | 6.69% | 0.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |